Pfizer’s bladder cancer treatment achieves main goal in late-stage trial

by
Contributor since / Followers

15 hours ago

Pfizer (NYSE:PFE) said on Friday it achieved main goal in late-stage trial evaluating sasanlimab in combination with Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.
The study demonstrated a clinically

Tags: PFE